Anthem Biosciences IPO: Anthem Biosciences will launch its initial public offering (IPO) worth Rs 3,395 crore on July 14. The public issue will close on July 16.
This issue is an offer for sale (OFS) by the company’s promoters, investors and other personnel material. This means that the company will not get any benefit from this issue and it will be purely a variety of advice. However, information like lot size and price band has not been disclosed yet.
Financial performance
The company reported revenue of Rs 1,844 crore in FY25, a 30 per cent year-on-year increase compared to Rs 1,419 crore in FY24. While its profit after tax (PAT) rose by 23 per cent to Rs 451 crore during the same period.
Listed peer firms
The company has several listed industry peers, some of which are leaders in the sector, including Sai Life Sciences Limited, Syngene International, Suven Life Sciences and Divi’s Laboratories.
Anthem Biosciences IPO: BRLMs, registrar details
JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India) are acting as the book-running lead managers for the IPO. The company has appointed Kfin Technologies Limited as registrar for the issues.
What does Anthem Bioscience do?
Founded in 2006, Anthem Biosciences is a Contract Research, Development, and Manufacturing Organisation (CRDMO) focused on innovation and technology. The company operates across the entire pharmaceutical value chain, including drug discovery, development, and manufacturing. It also produces and markets complex fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.
